What Genevia Technologies does

Genevia Technologies Oy is a privately held bioinformatics consulting firm headquartered in Tampere, Finland. The company delivers "bioinformatics as a service" to academic researchers, biotechnology companies, and pharmaceutical clients, providing expert-led omics data analysis across DNA-seq, RNA-seq, single-cell RNA-seq, spatial transcriptomics, epigenomics, and proteomics/metabolomics. Its core delivery model pairs customers with PhD-level bioinformaticians on project-based or dedicated FTE engagements, supported by custom analysis pipelines, multi-omics integration workflows, and an expanding set of AI-augmented capabilities including LLM-based in-silico drug screening, ADMET property prediction, BERT-driven biomedical literature mining, and ML-based neoantigen and tumor clonal evolution analyses.

The firm operates a tiered service portfolio spanning entry-level discovery engagements (Discovery Ticket at €1,250), advisory and review services (Bioinformatics Review, Experiment Design at €1,990, Grant Support at €5,950), coaching (Bioinformatics Mentor at €1,560 per 10 hours), and ongoing dedicated support through the Virtual Bioinformatics Core on 3–12 month FTE-based contracts. Go-to-market is sales-led, combining direct outreach, scientific content marketing, conference participation, and referral networks anchored by 18+ PhD bioinformaticians whose collective publication record exceeds 380 research articles and who have collectively served 180+ organizations since 2011.

Genevia is bootstrapped and founder-led by CEO and co-founder Antti Ylipää, with a senior team spanning R&D, operations, sales, and finance. The company has expanded into Germany and Sweden on top of its Finnish home market and serves customers across Europe and the United States. It holds ISO 9001 certification (2025) and is pursuing ISO 27001, and has begun commercializing an AI-driven drug discovery offering alongside associated sub-brands (RepurposeDrugs, DrugRepo, DrugTargetCommons), signaling an incremental pivot toward higher-value pharma R&D consulting.

Name

Genevia Technologies

Legal name

Genevia Technologies Oy

Website

https://geneviatechnologies.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Genevia Technologies is a Tampere, Finland-based bioinformatics consulting firm providing omics data analysis and AI-augmented drug discovery services to academic researchers and biotech/pharma clients, supported by 18+ PhD bioinformaticians serving 180+ organizations since 2011.

Ownership category

akta.pro rank

Product category

Bioinformatics Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)

akta.pro secondary industries

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Transcriptomics & Gene Expression Profiling Services (HLAGANAE), RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)

Keywords

• Bioinformatics services
• Omics data analysis
• Multi-omics integration
• AI drug discovery
• Computational biology consulting

Headquarters

HQ city

Tampere

HQ country

Finland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Bioinformatics Consulting Services: Genevia Technologies generates revenue through various bioinformatics service engagements including Virtual Bioinformatics Core (dedicated expert analysis), Bioinformatics Review (audit service), Bioinformatics Mentor (coaching), Discovery Ticket (initial assessment), Grant Support (grant application assistance), and Experiment Design. Services are priced at fixed rates or FTE-based monthly engagements with typical initial contracts of 3 months extendable monthly, or 12-month Enterprise plans.
2. AI-driven Drug Discovery Services: Specialized consulting services for AI-powered drug discovery and repurposing, including in-silico screening, ADMET prediction, and drug repurposing analyses for pharmaceutical and biotech clients.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels7 records

Core offering

Genevia Technologies provides Bioinformatics-as-a-Service, delivering expert omics data analysis (DNA-seq, RNA-seq, single-cell RNA-seq, spatial transcriptomics, epigenomics, proteomics/metabolomics) to academic researchers, biotech firms, and pharmaceutical companies. The firm also offers consulting services such as Virtual Bioinformatics Core, Grant Support, Experiment Design, Bioinformatics Mentor, Bioinformatics Review, Discovery Ticket, and specialized AI-driven drug discovery leveraging LLMs and predictive ML models for target identification, ADMET prediction, and drug repurposing.

Product overview

Genevia Technologies offers Bioinformatics as a Service through a portfolio of specialized omics data analysis services and consulting offerings. The core services include six types of sequencing and multi-omics data analysis: DNA-seq, RNA-seq, single-cell RNA-seq, spatial transcriptomics, epigenomics, and proteomics/metabolomics. These are complemented by service offerings including Virtual Bioinformatics Core (ongoing tailored analysis), Bioinformatics Mentor (coaching), Discovery Ticket (initial assessment), Bioinformatics Review (audit), Grant Support, and Experiment Design. The company also provides specialized AI-driven drug discovery services leveraging large language models and predictive analytics for pharmaceutical research. The service model provides flexible, expert bioinformatics support without requiring clients to hire permanent staff.

Differentiator

Problem solved

Functional benefit

Brands

• RepurposeDrugs: Interactive web-portal and predictive platform for repurposing mono- and combination therapies, developed by Dr. Ziaurrehman Tanoli at FIMM but associated with Genevia's AI-driven drug discovery services.
• DrugRepo
• DrugTargetCommons

Products and services

• DNA Sequencing Data Analysis Analysis of DNA sequence data from whole genomes, exomes, sequencing panels, SNP arrays, and metagenomic experiments to identify mutations, assemble genomes, and study genetic variation in populations of any species. Target users are life sciences researchers in academia, biotech, and pharma.
• RNA Sequencing Data Analysis Transcriptome-wide expression analyses for bulk RNA-seq, small RNA-seq, and other transcriptomic measurements to study molecular mechanisms in biological systems from single cells to complex microbiomes. Target users are life sciences researchers in academia and industry.
• Single-Cell RNA Sequencing Data Analysis Single-cell RNA-seq data analysis with integration across technology platforms, data types (including scATAC-seq), and species at scale and resolution unmatched by bulk sequencing. Target users are researchers studying cellular heterogeneity in academia, biotech, and pharma.
• Spatial Transcriptomic Data Analysis Analysis of spatial transcriptomics data providing molecular view of tissue organization, with experience in both developing new spatial transcriptomics technologies and applying them in tumors and normal tissues. Target users are researchers in oncology, neuroscience, and developmental biology.
• Epigenomic Data Analysis Analysis of most types of epigenomic sequencing and array data to characterize chromatin state, gain deeper understanding of gene regulation, and identify biomarkers for diseases. Target users are researchers in gene regulation, biomarker discovery, and disease mechanism studies.
• Proteomic and Metabolomic Data Analysis Pathway and biomarker analyses on protein and small molecule mass spectrometry data to reveal the functional state of biological systems. Target users are researchers in metabolism, endocrinology, and systems biology.
• Virtual Bioinformatics Core Fully tailored omics data analysis by a dedicated expert bioinformatician providing ongoing bioinformatics support across project stages, with FTE-based monthly engagements (typical 3-month initial term with monthly extension, or 12-month Enterprise plan). Target users are research groups and companies needing sustained bioinformatics capacity.
• Bioinformatics Review Expert audit service (positioned as 'Reviewer #0') reviewing omics data analysis, code, and manuscripts with a written expert assessment and priced quote for recommended follow-up work. Priced at €1,990 base + €990 per additional data type. Target users are research teams seeking independent validation of analysis quality.
• Grant Support Expert assistance for competitive grant applications including feasibility review, statistical and experimental design, budget and timeline estimation, provider screening, and formal letter of support. Priced at €5,950 fixed; grant planning provided at no cost when Genevia joins the proposal consortium. Target users are principal investigators preparing grant proposals.
• Discovery Ticket Low-commitment initial analysis service including dataset QC, exploratory insight, action plan, and results session. Priced at €1,250 fixed, with 100% of fee credited toward Virtual Bioinformatics Core engagement if started within 60 days. Target users are prospective clients evaluating Genevia before larger commitment.
• Bioinformatics Mentor One-on-one video coaching service (10-hour blocks) for scientists learning to analyze their own omics data, including method selection, live troubleshooting, result interpretation, and publication advice. Priced at €1,560 per 10-hour block, with additional 10-hour blocks available at same rate. Target users are researchers building in-house bioinformatics capabilities.
• Experiment Design

Quantifiable outcome

• 180+ organizations supported since 2011
• +1 more outcomes

Named customers12 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature6 records

Partnerships

One partnership is on record.

• CPCT Genomics Core of UMass BostonminorStrategic or Co-development Partner · 15 September 2022Partnership established between Genevia Technologies and CPCT Genomics Core at UMASS Boston for collaborative bioinformatics support and genomics services.

Scale indicators3 records

Recent moves10 records

Expansion highlights5 records

Direct peers

• Eagle Genomics: UK-based bioinformatics consulting and platform firm serving pharma, consumer goods, and food sectors with multi-omics analytics. Closest functional peer to Genevia's omics-as-a-service model and academic-adjacent client base.
• Phastar: Global biostatistics and data-science CRO serving pharma, biotech, and academia. Direct competitor for outsourced analytical support for clinical and translational studies, often working alongside omics vendors.

Broad incumbents

• Genedata: Swiss provider of enterprise bioinformatics platforms and professional services for pharma R&D. Comparable scope across omics analysis, multi-omics integration, and translational research workflows, but at a much larger scale and as a broader incumbent.
• Dotmatics: Enterprise scientific R&D informatics platform serving biology and chemistry workflows including omics. Comparable as a broad life-sciences informatics incumbent rather than a pure-play bioinformatics consulting firm.
• DNAnexus: Genomics and biomedical informatics cloud platform with a services arm supporting pharma and clinical customers. Comparable in serving multi-omics data workflows, though as a platform-and-tooling incumbent rather than a focused consulting boutique.
• Velsera (formerly Seven Bridges): Cloud bioinformatics platform and services provider for genomics, multi-omics, and clinical research. Comparable in offering both omics-as-a-service delivery and supporting infrastructure to academic and pharma customers.
• Q² Solutions: Large clinical and genomics-focused CRO with bioinformatics services embedded across trials and translational research. Overlaps with Genevia's clinical-research and biotech support, though at significantly larger scope and scale.

Others

• IDBS (Danaher): Provider of R&D data management and informatics solutions for biopharma, including omics-adjacent workflows. Comparable as an informatics vendor in the life-sciences data stack rather than a direct consulting peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/GeneviaLtd

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genevia Technologies